Sunshine Biopharma Inc (SBFM)

[FormerBroker]

I think Chad Brown's experience in therapeutic drugs is a big plus for Sunshine Biopharma. However, Aegis won't be able to pitch SBFM to their client network until SBFM is trading on NASDAQ. I know what I'm talking about. SBFM won't get to the NASDAQ until the results of either the preclinical antiviral drug or the cancer drug are released. Aegis will not risk their reputation on false claims by a micro biopharma company. Thorough due diligence of Sunshine Biopharma will reveal that the science is a huge game changer for humans worldwide. Sunshine has the science but needs the business acumen to break through the hurdles of govt and big pharma resistance.

Aegis Capital Corp. Announces the Addition of the RG Investment Group
September 29, 2021

https://irdirect.net/prviewer/release_only/id/4879342

"Prior to joining Aegis Capital, Chad served as Vice President at Wells Fargo Advisors' Private Client Group and UBS PaineWebber Inc. Additionally, Chad has an entrepreneurial background as a therapeutic drug patent holder, NIH grant author and biotechnology company chief executive and board member."